Ubs Group Ag Innoviva, Inc. Call Options Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2020 Jul 31, 2020	SELL	$11.49 - $15.26 $4.43 Million - $5.89 Million	-385,900 Reduced 78.48%	105,800 $1.48 Million
Q1 2020 May 01, 2020	BUY	$8.11 - $15.23 $329,266 - $618,338	40,600 Added 9.0%	491,700 $5.78 Million
Q4 2019 Feb 14, 2020	BUY	$10.28 - $14.38 $3.69 Million - $5.16 Million	358,500 Added 387.15%	451,100 $6.39 Million
Q3 2019 Nov 14, 2019	BUY	$10.05 - $14.55 $930,630 - $1.35 Million	92,600 New	92,600 $976,000

226

78.8M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.31B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.